Pressemitteilung BoxID: 690494 (BIOTRONIK)
  • Woermannkehre 1
  • 12359 Berlin
  • Ansprechpartner
  • Manuela Schildwächter
  • +49 (30) 689051414

Physicians Implant World's First ProMRI® Quadripolar CRT-D System to Treat Heart Failure

Patients Receive New BIOTRONIK Cardiac Resynchronization Therapy Implantable Defibrillators that Grant MRI Access and Reduce Shocks

(PresseBox) (Berlin, ) BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the first implantations worldwide of its new ICD and CRT-D series (implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators). With Sentus quadripolar leads and the Inventra series, BIOTRONIK offers the only devices for patients with heart failure worldwide that are approved for MRI use. The quadripolar Sentus lead eases the implantation process by giving physicians access to challenging vessels. With CE approval in early July, BIOTRONIK's new implantable defibrillator series includes the industry's first quadripolar left-ventricular leads to be approved for MRI use.

BIOTRONIK is the first and only company to offer heart failure patients cardiac resynchronization therapy devices and leads that can undergo MRI scans. As patients age, they may develop comorbidities, and MRI scans can be critical in diagnosing conditions like stroke, brain tumors or orthopedic conditions.

"My ICD and heart failure patients are frequently indicated for MRI scans to diagnose potential comorbidities," commented Dr. Antonio Curnis, Spedali Civili Hospital, Brescia, Italy, who implanted a new BIOTRONIK ProMRI® Inventra HF-T and Sentus quadripolar lead in a 73-year-old patient with congestive heart failure. "With BIOTRONIK devices, I know I can give my patients high-quality therapy and broad access to diagnostics."

In addition to ProMRI® technology, the new BIOTRONIK ICDs and CRT-Ds reduce inappropriate shocks with MorphMatch morphology detection criteria and anti-tachycardia pacing (ATP) optimization. While delivering shocks at the right time can save patients' lives, shocks should be minimized to appropriately control arrhythmias, improve patients' quality of life and increase device longevity.

Dr. Werner Jung, Schwarzwald-Baar Clinic, Villingen Schwenningen, Germany, successfully implanted a 72-year-old heart failure patient with a new ProMRI® CRT-D from BIOTRONIK. "BIOTRONIK has proved the exceptional quality of its products once again with the new ICDs and Sentus quadripolar leads," commented Dr. Jung. "Many heart failure patients are very ill and shocks put stress on the body and mind. By choosing a device with unique algorithms that reduce shocks, I am able to give my patients peace of mind and restore their sense of safety."

BIOTRONIK has included its Closed Loop Stimulation (CLS) technology in ICDs for the first time. CLS helps patients experience the most natural rate adoption possible by utilizing their neurological information. It is the only system that allows pacemakers, and now ICDs, to react naturally to patients' physical as well as mental activity or stress.

First Implanters of the New Defibrillator Series Are:
- Dr. Antonio Curnis, Spedali Civili Hospital, Brescia, Italy;
- Dr. Werner Jung, Schwarzwald-Baar Clinic, Villingen Schwenningen, Germany;
- Dr. Tiziano Moccetti and Dr. Angelo Auricchio, Cardiac Center Ticino, Lugano, Switzerland;
- Dr. Anthony Stanley, Sunninghill Netcare Hospital, Johannesburg, South Africa;
- Dr. Martin Winterhalter, SRH Clinic, Gera, Germany.

Website Promotion


One of the world's leading manufacturers of cardio- and endovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. With high-quality Sentus and Corox leads, BIOTRONIK has one of the broadest CRT lead portfolios on the market and offers the only products that allow heart failure patients with a CRT device to undergo MRI scans. With BIOTRONIK Home Monitoring®, physicians can remotely monitor their heart failure patients' clinical and device status for proven early detection and safe follow-up reduction. Physicians can adapt therapies early and prevent the worsening of underlying conditions, stroke or hospitalizations.

For more information, visit: